Status:

TERMINATED

A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma

Lead Sponsor:

Celgene

Conditions:

Multiple Myeloma

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

Study CC-99712-MM-001 is an open-label, Phase 1, dose escalation (Part A) and expansion (Part B), First-in-Human (FIH) clinical study of CC-99712 in monotherapy or combination with BMS-986405 in parti...

Eligibility Criteria

Inclusion

  • Participants must satisfy the following criteria to be enrolled in the study:
  • Inclusion
  • Participant is ≥ 18 years of age at the time of signing the ICF.
  • Participant has a history of multiple myeloma (MM) with relapsed and/or refractory disease
  • Participant must have measurable disease.
  • Participant has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.
  • Exclusion Criteria
  • Participant has symptomatic central nervous system involvement of MM.
  • Participant had a prior autologous stem cell transplant ≤ 3 months prior to starting CC-99712.
  • Participant had a prior allogeneic stem cell transplant with either standard or reduced intensity conditioning ≤ 6 months prior to starting CC-99712 or is on systemic immunosuppression for graft-versus host disease.
  • Subject is a pregnant or lactating female.
  • Subject has known human immunodeficiency virus (HIV) infection.
  • Subject has active hepatitis B or C (HBV/HCV) infection.
  • Other protocol-defined inclusion/exclusion criteria apply

Exclusion

    Key Trial Info

    Start Date :

    August 26 2019

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    August 19 2024

    Estimated Enrollment :

    47 Patients enrolled

    Trial Details

    Trial ID

    NCT04036461

    Start Date

    August 26 2019

    End Date

    August 19 2024

    Last Update

    August 30 2024

    Active Locations (20)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 5 (20 locations)

    1

    Local Institution - 107

    La Jolla, California, United States, 92093

    2

    Local Institution - 105

    Sarasota, Florida, United States, 34232

    3

    Local Institution - 103

    Buffalo, New York, United States, 14263

    4

    Local Institution - 106

    New York, New York, United States, 10029